Study area

Project MIMESIS aims to scale-up ENYO Pharma’s systems biology approach to discover original preclinical assets against human targets not previously considered tractable for drug development in both infectious and non-infectious disease contexts. It will address 6 diseases with unmet clinical need:

Infectious diseases



Influenza is an infectious disease caused by an influenza virus. Symptoms can be mild to severe and the global burden of seasonal flu to the public remains serious with illness, hospitalizations, and deaths every year.


Human RhinoVirus (HRV)

HRV is the most common viral infectious agent in humans and is the predominant cause of the common cold and has no known treatment. They may be an important cause of exacerbations in asthma and chronic obstructive pulmonary disease. The large genetic diversity of HRV strains makes ENYO’s host directed therapeutic approach well suited for this pathogen.


Respiratory Syncytial Virus (RSV)

RSV causes respiratory tract infections. It is a major cause of lower respiratory tract, and a significant health threat annually, especially for infants and older adults.


Zika virus (ZIKV)

ZIKV is a mosquito-borne virus also transmitted by sexual intercourse and causes an infectious disease where symptoms, when present, are usually mild. In contrast, infection during pregnancy can cause serious brain defects in the developing fetus. Reported in many countries and is likely to continue to spread to new areas. No known treatment.


Tuberculosis (TB)

TB is an infectious disease caused by the bacterium Mycobacterium tuberculosis (MTB) and generally affects the lungs. Globally, in 2014, 9.6 million people contracted TB and, if not treated properly, TB disease can be fatal. Strains resistant to current therapy are rapidly emerging.

Non Infectious disease


Triple negative Breast cancer

Breast cancer is one of the most common forms of cancer and, depending on the stage of its diagnosis, triple negative breast cancer can be particularly aggressive, unresponsive to therapy and more likely to recur than other subtypes of breast cancer.

EU flag

EU-funded Project

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement n° 739086-MIMESIS.